Advanced search
Publication Cover
Acta Cardiologica Volume 74, 2019 - Issue 2
Submit an article Journal homepage
83
Views
4
CrossRef citations to date
0
Altmetric
Original Scientific Paper

Alteration at transcriptional level of cardiac renin–angiotensin system by letrozole treatment

Shahnaz ShekarforoushDepartment of Physiology, Arsanjan Branch, Islamic Azad University, Fars, Iran; Correspondence[email protected] [email protected]
,
Farhad KoohpeymaEndocrine and Metabolism research center, Shiraz University of Medical Sciences, Shiraz, Iran;
&
Fatemeh SafariBiotechnology Research Center, International Campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; ;Department of Physiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Pages 109-113 | Received 22 Dec 2017, Accepted 24 Apr 2018, Published online: 17 Jun 2018

References

  • Cuglan B, Soran O. The adverse cardiovascular effects of aromatase inhibitors and its management in patients with breast cancer. International Heart and Vascular Disease Journal. 2013;1:30–43.
  • Franik S, Kremer JA, Nelen WL, et al. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2014;(2):CD010287.
  • Satyanarayana P, Murali M. Development and validation of LC method for the estimation of letrozole in pharmaceutical dosage form. Int. J. Res. Pharm. Biomed. Sci. 2011;2:1047–1051.
  • Khouri MG, Douglas PS, Mackey JR, et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation. 2012;126:2749–2763.
  • Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747–2757.
  • Arumugam A, Lissner EA, Lakshmanaswamy R. The role of hormones and aromatase inhibitors on breast tumor growth and general health in a postmenopausal mouse model. Reprod Biol Endocrinol. 2014;12:66.
  • Seruga B, Zadnik V, Kuhar CG, et al. Association of aromatase inhibitors with coronary heart disease in women with early breast cancer. Cancer Invest. 2014;32:99–104.
  • Guimaraes S, Pinheiro H. Functional evidence that in the cardiovascular system AT1 angiotensin II receptors are AT1B prejunctionally and AT1A postjunctionally. Cardiovasc Res. 2005;67:208–215.
  • Wollert KC, Drexler H. The renin-angiotensin system and experimental heart failure. Cardiovasc Res. 1999;43:838–849.
  • Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol. 1992;54:227–241.
  • Dorri Mashhadi F, Zavvar Reza J, Jamhiri M, et al. The effect of resveratrol on angiotensin II levels and the rate of transcription of its receptors in the rat cardiac hypertrophy model. J Physiol Sci. 2017;67:303–309.
  • Kumru S, Yildiz AA, Yilmaz B, et al. Effects of aromatase inhibitors letrozole and anastrazole on bone metabolism and steroid hormone levels in intact female rats. Gynecol Endocrinol. 2007;23:556–561.
  • Park E, Abu-Khalaf MM, Hatzis C, et al. Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer. J Clin Oncol (Meeting Abstract). 2014;32:e11501.
  • Skytta T, Tuohinen S, Virtanen V, et al. The concurrent use of aromatase inhibitors and radiotherapy induces echocardiographic changes in patients with breast cancer. Anticancer Res. 2015;35:1559–1566.
  • Studer R, Reinecke H, Muller B, et al. Increased angiotensin-I converting enzyme gene expression in the failing human heart. Quantification by competitive RNA polymerase chain reaction. J Clin Invest. 1994;94:301–310.
  • Ferreira-Machado SC, Rocha Nde N, Mencalha AL, et al. Up-regulation of angiotensin-converting enzyme and angiotensin II type 1 receptor in irradiated rats. Int J Radiat Biol. 2010;86:880–887.
  • Harada K, Sugaya T, Murakami K, et al. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation. 1999;100:2093–2099.
  • Van Esch Jh, Gembardt F, Sterner-Kock A, et al. Cardiac phenotype and angiotensin II levels in AT1a, AT1b, and AT2 receptor single, double, and triple knockouts. Cardiovasc Res. 2010;86:401–409.
  • Toko H, Oka T, Zou Y, et al. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res. 2002;25:597–603.
  • Paradis P, Dali-youcef N, Paradis FW, et al. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA. 2000;97:931–936.
  • Gonzalez A, Lopez B, Diez J. Fibrosis in hypertensive heart disease: role of the renin-angiotensin-aldosterone system. Med Clin North Am. 2004;88:83–97.
  • Johren O, Dendorfer A, Dominiak P. Cardiovascular and renal function of angiotensin II type-2 receptors. Cardiovasc Res. 2004;62:460–467.
  • Passier RC, Smits JF, Verluyten MJ, et al. Expression and localization of renin and angiotensinogen in rat heart after myocardial infarction. Am J Physiol. 1996;271:H1040–H1048.
  • Kobori H, Ichihara A, Suzuki H, et al. Role of the renin-angiotensin system in cardiac hypertrophy induced in rats by hyperthyroidism. Am J Physiol. 1997;273:H593–H599.
  • Finckh M, Hellmann W, Ganten D, et al. Enhanced cardiac angiotensinogen gene expression and angiotensin converting enzyme activity in tachypacing-induced heart failure in rats. Basic Res Cardiol. 1991;86:303–316.
  • Haines CD, Harvey PA, Leinwand LA. Estrogens mediate cardiac hypertrophy in a stimulus-dependent manner. Endocrinology. 2012;153:4480–4490.
  • Aliabadi E, Namavar MR, Mortezaee K, et al. Kisspeptin expression features in the arcuate and anteroventral periventricular nuclei of hypothalamus of letrozole-induced polycystic ovarian syndrome in rats. Arch Gynecol Obstet. 2017;296:957–963.
  • Maliqueo M, Sun M, Johansson J, et al. Continuous administration of a P450 aromatase inhibitor induces polycystic ovary syndrome with a metabolic and endocrine phenotype in female rats at adult age. Endocrinology. 2013;154:434–445.
  • Jessup JA, Zhang L, Chen AF, et al. Neuronal nitric oxide synthase inhibition improves diastolic function and reduces oxidative stress in ovariectomized-mRen2.Lewis rats. Menopause. 2011;18:698–708.
  • Wassmann S, Baumer AT, Strehlow K, et al. Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats. Circulation 2001;103:435–441.
  • O'donnell E, Floras JS, Harvey PJ. Estrogen status and the renin angiotensin aldosterone system. Am J Physiol Regul Integr Comp Physiol. 2014;307:R498–R500.
  • Zimmerman MA, Sullivan JC. Hypertension: what's sex got to do with it? Physiology (Bethesda). 2013;28:234–244.
  • Bhavnani BR, Stanczyk FZ. Pharmacology of conjugated equine estrogens: efficacy, safety and mechanism of action. J Steroid Biochem Mol Biol. 2014;142:16–29.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.